Drug Trial Radar · NCT07847697
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jun 30, 2029
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants
Conditions
- Healthy Participants
Interventions
SCTB10Drug
SCTB10 will be subcutaneously administered as a single dose in healthy volunteers
PlaceboDrug
Placebo will be subcutaneously administered in Healthy Volunteers
Primary outcomes
What the sponsor says the trial is designed to measure.
- dose limited toxicity (DLT).Time frame: Up to approximately 6 weeks.
- Incidence of TEAE.Time frame: Up to approximately 25 weeks.
- Incidence of TRAE.Time frame: Up to approximately 25 weeks.
- Incidence of SAE.Time frame: Up to approximately 25 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.